knowledge -WSS

knowledge

author：entertainment 2025-09-28 00:48:06 - browse：813

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Doctors' information doesn't help them choose wisely when sick

focus

WSS

Study says nonprofit hospitals fall short in charity care spending

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

BioAge raises $170M for combination therapy with Zepbound

Medicare threatens to cut off funding for HCA's Mission hospital

KalVista pill reduced swelling 'attacks' caused by genetic disease

The Readout: Gilead, Bernie Sanders, and other pharma news

explore

knowledge

focus

Bright Health sells Medicare Advantage business to Molina

Eliminate the waiting period for sterilization covered by Medicaid

23andMe had bad news about my health. I wish a person had delivered it

The Readout: Gilead, Bernie Sanders, and other pharma news

BioMarin wins approval for gene therapy to treat hemophilia A

Key House Republican on health care plans exit from Congress

What does generative AI mean for health care? We asked experts

Why did Pfizer dish out millions for a Super Bowl ad?

Drug repurposing or repositioning? The language matters

What we’ve learned from the Aduhelm mess

entertainment

To avoid data mishandling cases, universities eye AI and other tools

The Readout: Gilead, Bernie Sanders, and other pharma news

PhRMA lawsuit over Medicare drug price negotiation tossed

What we’ve learned from the Aduhelm mess

Vertex Pharmaceuticals may move headquarters in Boston

There's no autism epidemic. It's an autism diagnosis epidemic

explore

focus

knowledge

knowledge